Halozyme Therapeutics Inc.
NASDAQ · HALO·San Diego, CA·Large-cap·Approved
Enzyme-based drug delivery company with the ENHANZE (rHuPH20) technology platform enabling subcutaneous formulations of biologics across oncology and immunology. Halozyme earns royalties from major pharma partners (Roche, J&J, Pfizer, argenx) and markets proprietary oncology assets.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Halozyme Financial Update January 2024 | Corporate overview | January 1, 2024 | 31 |